Day: March 16, 2022

Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer

• Proceeds to support the further development of lead asset KIT2014 in cystic fibrosis through to Phase 1/2A clinical trial
• International syndicate of new investors including Claris Ventures, 2 Invest, 3B Future Health Fund and Alef 6, with continued support from existing investors
• Appointment of Dr. Metzler as CEO brings extensive international pharmaceutical experience as Kither Biotech accelerates development of its lead candidates

Turin, Italy, 16 March 2022 – Kither Biotech (“Kither” or “the Company”), a biopharmaceutical company developing novel therapies for rare respiratory diseases, today announces that it has raised €18.5 million in a Series B financing round and has appointed current Board Member Dr. Vincent Metzler as Chief Executive Officer.

Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell-permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells. cAMP levels are directly associated with the pathogenesis of CF including mucus accumulation, inflammation, and bronchoconstriction. KIT2014 is currently being developed as an add-on to the current standard of care enabling improved efficacy by directly focusing on the most significant ailments of CF patients, delivered directly to the lungs as an inhaled therapy. The Company expects to complete pre-clinical studies in 2022 and begin a Phase 1/2A clinical trial of KIT2014 soon thereafter.

The financing round will also enable Kither to begin expanding and diversifying its pipeline of products for the treatment of rare pulmonary diseases by launching the pre-clinical development of KITCL27, a small molecule PI3K inhibitor pro-drug being developed as a monotherapy for idiopathic pulmonary fibrosis.

The fundraise was co-led by new investors Claris Ventures and 2 Invest, with participation from 3B Future Health Fund and Alef 6. Existing investors CDP Venture Capital SGR, Italian Angels for Growth, Ersel, Club degli Investitori and ACE Venture also joined the financing round. Pietro Puglisi, Partner at Claris Ventures and Heikki Lanckriet, CEO of 4BaseBio will join Kither’s Board of Directors.

Kither also announces today the appointment of Dr. Vincent Metzler as Chief Executive Officer, while current CEO Marco Kevin Malisani transitions to the role of Chief Financial Officer and remains a member of the Board of Directors. Dr. Metzler has served on the Board of Directors of Kither since June 2020, bringing more than 20 years of experience in commercial operations in pharma and biotech. Prior to joining Kither, Dr. Metzler was Vice President, Head of Marketing and Commercial Operations, Europe, at immunotherapy company Atara Biotherapeutics, and a member of the Executive Leadership Team of Wilson Therapeutics, a Swedish biotech clinical-stage company.

The Board of Directors will be chaired by Laura Iris Ferro, early investor in Kither and founder of Gentium, acquired by Jazz Pharmaceuticals for $1bn.

Dr. Vincent Metzler, CEO at Kither Biotech, commented: “Kither is committed to developing transformative therapies for patients living with rare pulmonary diseases. The fundraise marks a pivotal moment for the Company as we progress our first product into the clinic and further expand our product pipeline. We are proud to have the support of this high-quality syndicate of investors as we drive forward to our next stage of growth.”

Pietro Puglisi, Managing Partner at Claris Ventures, and Hansjörg Plaggemars, CEO of 2Invest, said: “We are thrilled to support Kither Biotech as it prepares to enter the clinic with its lead candidate KIT2014. This is a very exciting time for the Company, and we welcome the appointment of Dr. Vincent Metzler, a highly experienced executive, as CEO. With its high-quality science, expert leadership team, and strong syndicate of investors, Kither Biotech is ideally positioned to accelerate the clinical development of its therapies for the benefit of millions of patients affected by rare respiratory diseases.”

Heikki Lanckriet, newly appointed Non-executive Director at Kither Biotech said: “I am excited to join the Kither Biotech board of directors at such an exciting phase. As the team strives to develop innovative therapies for the treatment of cystic fibrosis and expand its pipeline of treatments for respiratory diseases, I look forward to be supporting the Company’s ambitions alongside such a high-quality syndicate of investors.”

Marco Kevin Malisani, Co-Founder, CFO and Executive Director at Kither Biotech, added: “This financing round represents a transformational moment for Kither, further strengthening our shareholder base and our management team. Starting off as an academic spin-off from the University of Torino and Novara we have been able to attract numerous established investors: this is a clear demonstration of our cutting-edge science. I am also pleased to welcome the appointment of Dr. Vincent Metzler as CEO: his extensive international pharmaceutical experience will be invaluable as we accelerate the development of our promising therapeutic candidates.”

ENDS

About Kither Biotech

Kither Biotech is a biopharma company founded by Prof. Alessandra Ghigo, Prof. Emilio Hirsch, Prof. Alberto Bardelli and Marco Kevin Malisani. The company aims to identify and develop new drug candidates for the treatment of rare pulmonary diseases, with specific focus on cystic fibrosis and idiopathic pulmonary fibrosis. Kither Biotech is a spin-off from the University of Turin and actively collaborates with the Molecular Biotechnology Center (University of Turin) and other research centres in the world. The company developed a pipeline of treatments currently under preclinical development, with programs in cystic fibrosis, idiopathic pulmonary fibrosis and other respiratory diseases. |www.kitherbiotech.com

About KIT2014

KIT2014 is a cell-permeable cAMP modulating peptide that disrupts the interaction of PI3Kgamma with its partner, protein kinase A (PKA), leading to type 3 and 4 phosphodiesterases (PDE3/4) inhibition and, in turn, to enhanced cAMP responses within the cell. KIT2014 is currently being investigated for the treatment of cystic fibrosis (CF) as an add-on inhalation therapy to the current standard of care, enabling improved efficacy by directly impacting mucus hypersecretion, airway inflammation and bronchoconstriction, the most significant ailments of CF patients. When inhaled, KIT2014 increases cAMP locally in bronchial epithelial cells to promote the opening of CFTR chloride channels, which are key to mucus hydration, while in lung smooth muscle and immune cells cAMP elevation limits bronchoconstriction and neutrophil infiltration. In CF patients, treatment with KIT2014 is believed to restore the function of CFTR mutants by potentiating the effects of CFTR modulators (Ghigo et al., Science Translational Medicine, in press).

For more information please contact:

Consilium Strategic Communications Matthew Cole / Davide Salvi / Lucie Foster KitherBiotech@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Jeito Capital co-leads EUR 80 million Series B financing in
European oncology company, Precirix

• Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.
• The financing will allow Precirix to advance its pipeline of precision radiopharmaceuticals.

Paris, France, 16 March 2022 – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led an investment of €80 million in Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology. The Belgian biotech company was created in 2014 as a spin-off from the Vrije Universiteit Brussel (VUB), one of the best European centers for medical research, and is dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals.

Jeito has co-led this investment with INKEF Capital and Forbion, two other leading European Life Sciences funds. Sabine Dandiguian, Managing Partner at Jeito, will join Precirix’s Board of Directors.

The proceeds will fund the development and expansion of Precirix’s pipeline. The company will advance its lead product candidate, CAM-H2, through its ongoing Phase I/II study, and plans to bring additional novel radiopharmaceuticals to the clinic.

While radiopharmaceuticals have proven clear clinical benefits for several decades, the field is advancing significantly in recent years and Precirix’s innovative and differentiated platform aims to provide a new hope to many new patient populations. Precirix’s platform brings together several unique features and facilitates the development of radiolabelled single domain antibodies (sdAbs) for multiple targets, in combination with different isotopes and applicability in various settings. Precirix’s lead product candidate, CAM-H2, is currently in a Phase I/II study for the treatment of HER2-positive metastatic breast and gastric cancer. Following the absence of any dose-limiting toxicities in the first cohort and a positive review from the Safety Review Committee, patients are now being enrolled in the second cohort of the dose-escalation phase.

With this new and ninth investment, Jeito Capital continues its mission to build a diversified portfolio of future European leaders with potentially groundbreaking therapies for the benefit of patients in areas of unmet needs.

Dr Rafaèle Tordjman, Founder and CEO at Jeito Capital, said: “We are pleased to have co-led this financing in Precirix alongside other high-quality European investors. At Jeito, we are continuing to identify and invest in companies in Europe that have the potential to be market leaders in the development of new and improved therapies for patients in areas of unmet need. Precirix is a clinical stage company which has the potential to significantly improve the lives of new patient populations with its targeted precision radiopharmaceuticals. We look forward to supporting the growth of the company in the long term as it builds its disruptive pipeline and accelerates the development and approval of next generation therapies for patients.”

Sabine Dandiguian, Managing Partner at Jeito Capital, said: “We are thrilled to co-lead this round with the ambition to support the company to bring a new alternative to patients suffering from advanced cancer, in total coherence with Jeito’s mission which is to “go faster to the patient, further with the entrepreneur.”

Ruth Devenyns, CEO of Precirix, added: “We are delighted to announce this major milestone and are grateful for the strong investor support. The addition of Inkef, Jeito and Forbion, three leading VC-funds in the healthcare sector, significantly reinforces our international shareholder base. The investment will allow Precirix to accelerate its growth trajectory and to further validate and broaden the technology platform.”

About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe and the United States. Jeito Capital has €534 million under management and has already built a strong portfolio of diversified companies, rapidly growing. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito_life or LinkedIn.

About Precirix NV
Precirix is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labelled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment.

For more information please contact:

Jeito Capital
Rafaèle Tordjman
Assia Mouhout, Executive Assistant
assia@jeito.life
Tel : +33 6 76 49 37 94
French media: TBWA Corporate
Marion Bougeard
Marion.bougeard@tbwa-corporate.com
Tel : +33 6 76 73 57 31

International media: Consilium Strategic Communications
Mary-Jane Elliott / Melissa Gardiner / Davide Salvi / Kris Lam
Jeito@consilium-comms.com
Tel: +44 (0) 20 3709 5700

Please click HERE for press release in French

Longest Continuous Light Walk in Vivid Sydney History; Global Storytellers Aaron Sorkin, Gretchen Carlson & Troye Sivan Headline Vivid Ideas; World Premiere of ‘The Gospel According to Marcia,’ UK’s Spiritualized & Baxter Dury to Rock Vivid Music; First Nations Artwork Yarrkalpa – Hunting Ground, 2021 Animated for Sydney Opera House Lighting of the Sails; Plus, First-Ever Vivid Sydney Dinner

SYDNEY, March 16, 2022 (GLOBE NEWSWIRE) — Destination New South Wales (NSW) is proud to announce its program lineup for Vivid Sydney 2022. Vivid Sydney 2022 will transform Sydney city into an illuminating fusion of creativity, innovation, and technology from Friday 27 May to Saturday 18 June, with more than 200+ events celebrating the essence of Sydney’s soul including its diversity, beauty, resilience, First Nations culture, and vibrant creative community.

Minister for Enterprise, Investment and Trade, Minister for Tourism and Sport and Minister for Western Sydney Stuart Ayres said, “The Vivid Sydney 2022 program is bursting with new events, venues, performances, and experiences, providing even more reasons to visit time and time again. This year, we are celebrating the festival’s 12th anniversary, with a bigger, brighter, and more brilliant lineup than ever before.

“Audiences will feel energised and invigorated by a number of festival firsts. This includes the longest-ever continuous Light Walk winding all the way from the Sydney Opera House to Central Station, the Vivid Sydney Dinner, Vivid Sydney Supper Club, and more, as well as all the innovative light-art installations, projections, eclectic music performances, and thought-provoking talks we all know and love.

“Vivid Sydney is an open invitation for Sydneysiders and visitors from Australia and the world to come and experience Sydney city at its creative best after dark. The 2022 festival has been two years in the making and is not to be missed,” Ayres said.

Festival Director Gill Minervini, who will deliver her first Vivid Sydney in 2022, said this year’s program captures the essence of Sydney’s soul, exploring what makes the city so unique. “Vivid Sydney tells a compelling story of creativity, innovation, and technology through light, music, and ideas that is distinguishably Sydney, yet authentically universal. The 2022 program delivers fresh and engaging content, bringing feelings of joy, excitement, wonder, inspiration, and hope to all who are innately drawn to it,” she said.

In 2022, 11 Sydney Central Business District (CBD) locations will ignite, two of which are new, with Circular Quay, Sydney CBD, The Rocks, Barangaroo, Darling Harbour, Darling Square, Darling Quarter, The Goods Line, Central Train Station, Luna Park, and Taronga Zoo, all coming to life with a mesmerising kaleidoscope of light artworks to wow visitors and locals alike.

Staged over 23 nights, the festival will deliver mesmerising art displays, 3D light projections, uplifting live music performances, and deep-dive discussions from the world’s brightest minds. Plus, in a festival first, the renowned Light Walk will stretch continuously for 8km, linking the Sydney Opera House to Central Train Station, with more than 200 LED sculptural birds guiding the way as part of the Future Natives installation.

The full 2022 Vivid Sydney media kit, program announcement, and high-res imagery, including 2022 Vivid Sydney light renders and broadcast-quality video footage of previous festivals’ highlights, are available to download at www.vividsydney.com/news-room.

MEDIA CONTACTS:

Greg Vekiarellis, Ogilvy PR
M: +61 401 873 217
E: greg.vekiarellis@ogilvy.com.au

Wayne Mitcham, Āmio Limited
M: +64 21 499 550
E: wayne@amio.nz

About Vivid Sydney

Vivid Sydney is an annual celebration of creativity, innovation, and technology, which transforms Sydney for 23 days and nights. Staged for its 12th year in 2022, Vivid Sydney fuses mesmerising art displays and 3D light projections with exhilarating live music performances and deep-dive discussions from some of the world’s brightest minds, as well as the Sydney Opera House Lighting of the Sails. Vivid Sydney is owned, managed, and produced by Destination NSW, the NSW Government’s tourism and major events agency.

Related Images

Image 1: Sails of the Sydney Opera House

Credit: Destination NSW

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Sails of the Sydney Opera House

Acclaimed Investors Include Co-Founders of Twitch, Rotten Tomatoes, Crunchyroll, Kabam, 9GAG, Junglee Games, and More

BANGALORE, India, March 16, 2022 (GLOBE NEWSWIRE) — TOONSUTRA, the India-focused mobile webtoon startup that has been incubating in stealth mode, announced it closed an oversubscribed pre-seed round for US$1.1 million. The new startup was incubated at leading character entertainment company Graphic India and was founded by media entrepreneur Sharad Devarajan.

TOONSUTRA is building India’s first “Webtoons meets Web3″ platform with a mission to become India’s new storytelling home for disruptive creators across the country to experiment, innovate and create engaging webtoon comic stories and digital collectibles for India’s 650 million+ mobile youth market.

The funds came from an acclaimed group of global investors and entrepreneurs including, Patrick Lee, Co-Founder, Rotten Tomatoes; Kevin Lin, Co-Founder, Twitch; Kun Gao, Co-Founder, Crunchyroll; Jeremy Liew, Partner, Lightspeed Venture Partners; Holly Lui, Co-Founder, Kabam; Ray Chan, Co-Founder, 9GAG; Rishad Tobaccowala, Former Chief Growth Officer, Publicis Group; Michael Maher, Founder, Start Media; Vishal Anand, Former Chief Product Officer, Dailyhunt; Benjamin Grubbs, Co-Founder, CreatorPlus; George Nolfi, filmmaker; Sandeep Kumar Sood, Co-Founder, Junglee Games; and others.

In addition to some of the biggest comic book libraries from around the world, the platform will showcase and promote emerging rising star creators across India and give them a home to tell their stories. The TOONSUTRA app will feature a wide range of content for audiences across superhero, fantasy, romance, sci-fi, Bollywood, mythology, action, and more.

“TOONSUTRA will become India’s new storytelling home for disruptive creators across the country to experiment, innovate and create powerful new webtoon comic stories and web3 collectibles and experiences,” TOONSUTRA founder Sharad Devarajan commented. “Webtoon platforms have become an explosive phenomenon across Asia, with top webtoon apps cumulatively reaching over 70 million monthly users and over a 100 billion views a year. For the first time, we want to make a webtoon app dedicated for Indians to spark a mobile comic and Web3 collectible revolution.”    

The new startup was incubated at Graphic India, the country’s highest-quality comic book producer and the creators of hit animated shows like Baahubali: The Lost Legends, Chakra The Invincible, and The Legend of Hanuman. Graphic India’s short-form-video-formatted Audio Comics and Motion Comics have already broken over 200 million cumulative views across third-party platforms in India, proving the growing demand for digital comics in the market.

Devarajan brings decades of character entertainment experience to the startup and is also an adjunct professor at Columbia Business School, where he has been teaching on AI, AR, VR and the Metaverse for over seven years, making him an early business school professor focused on the metaverse and its potential to disrupt media and society.

In December of last year, Graphic India partnered with leading and acclaimed NFT entertainment company Orange Comet to launch the “Chakraverse” collection, based on the Indian superhero Chakra The Invincible. The collection was launched with GaurdianLink on Beyondlife.club and resulted in the most successful U.S.-India NFT sale in history, selling out of over 12,000 digital collectibles, with each drop sold in less than one minute after being available. People from 14 countries participated in the auction, with 22% of the audience residing in India — showing the potential for digital character entertainment collectibles in India.

Graphic India’s vast library of high-quality comics will be available on TOONSUTRA. In addition to Indian content, the TOONSUTRA app will feature some of the biggest international comics from around the world available in vernacular Indian languages for the first time. In addition, exclusive digital collectibles based on Indian and global properties will be available exclusively offered.

People can find out more information and sign up for the launch at TOONSUTRA.com

The app is expected to launch widely in India in Q2 of this year.

For further information, please contact Nitika Ashalpara at press@TOONSUTRA.com.

Related Images

Image 1: DEVI – an Indian Superhero

One of the Indian superheroes featured on TOONSUTRA

Image 2: TOONSUTRA Webtoon App

A Sample Webtoon Comic on TOONSUTRA

Image 3: TOONSUTRA Logo

Image 4: Shadow Tiger – an Indian Superhero

An Indian superhero featured on TOONSUTRA

Image 5: TOONSUTRA App

This content was issued through the press release distribution service at Newswire.com.

Attachment

• DEVI – an Indian Superhero

All digital flexible packaging company doubles down on growth strategy

Austin, Texas USA, March 16, 2022 (GLOBE NEWSWIRE) — Established in 2016, and just 6 years old, ePac Flexible Packaging is doubling down on the aggressive growth strategy it has deployed since the company’s creation. ePac will continue to focus on helping small and medium brands achieve big brand presence, recognizing the importance of this sector in driving economic growth in all corners of the globe.

2021 was a strong year for the company, again seeing sales growth in excess of 50% YoY, and an increase in production capacity of over 30%. In North America new plants were successfully opened in Portland, Toronto, and Kansas City, and internationally in the UK, France, Poland, and Australia. ePac now operates 17 plants in North America and 6 more in Europe and Asia Pacific.

Looking forward into 2022-2023, ePac will continue expansion in North America, adding plants in the Northeast, Midwest, Southeast, Southwest, and a second location in the Mountain region. Additionally, print and pouch making capacity will be increased in existing ePac operations.

On the international front, ePac has brought on 2 senior executives, Sanjit Menezes and Paul Rason to lead growth initiatives in the Asia Pacific and MENA regions. Focusing on these markets will complement ePac’s growth in Europe, overseen by Managing Director, Johnny Hobeika.

To provide easy access to ePac’s services the company has begun to roll-out its own e-commerce platform, coupled with web-to-print and automated workflow. These technological advancements are unique to ePac and will greatly simplify how customers order flexible packaging while opening up ePac’s services to new market segments.

The company will also launch several new flexible packaging product lines, as well as an expanded roll-out of its connected packaging solution, ePacConnect.

According to ePac’s Chief Operating Officer, Virag Patel: “Although we are navigating through uncharted waters from a global economic perspective, we continue to see broad market acceptance for our services. With 6 years of operation under our belt, we are more convinced than ever that ePac can continue to help brands of all sizes grow while being accretive to the communities we serve”.

About ePac Flexible Packaging 

Founded in 2016 with a mission to help small and medium sized companies grow and compete with larger brands, ePac has 23 locations across the United States, Canada, Europe and the Asia Pacific region.  ePac is 100% digital and built on the latest in digital printing and workflow technologies, providing fast time to market and low minimum orders. ePac offers a full complement of sustainable film options, while its print technology platform is carbon-neutral and inherently eco-friendly. Further, the company offers true order to demand capability, helping brands reduce inventory and obsolescence.

For more information, please visit​ ​epacflexibles.com.

Attachment

• ePac Press Release

Carl Joachim
ePac Flexible Packaging
+1 561-573-7992
cjoachim@epacflexibles.com

Amber Group’s Co-Founder & CEO Receives “Top 100 Innovation CEO of 2022 Award”.

LONDON, England, March 16, 2022 (GLOBE NEWSWIRE) — Michael Wu is co-founder and CEO of Amber Group, a leading global digital asset company. Prior to founding Amber Group, Michael was a quantitative analyst at Goldman Sachs, a macro trader at Morgan Stanley, and a portfolio manager at a billion-dollar hedge fund. Michael is a member of Mensa International and a 2019 Forbes 30 Under 30 Asia honoree.

Founded in 2017, Amber Group is a leading global digital asset company operating globally with offices in Asia, Europe, and the Americas. Amber Group provides a full range of digital asset services spanning investing, financing, trading, and spending. Its 24/7 trading desk serves over a thousand institutional clients globally while the integrated digital asset platform WhaleFin serves the individual investors via mobile and desktop applications.

To date, Amber Group has raised a total of $328 million in funding from world-class investors including Temasek, Sequoia Capital, Paradigm, Tiger Global Management, Dragonfly Capital, Pantera Capital, Coinbase Ventures and Blockchain.com. Amber Group’s Series B + funding round of $200M valued the company at $3B.

In recognition of Amber Group’s advancement of the digital assets management industry, World Biz Magazine has awarded Michael Wu a position within the Top 15 of the global list of 100 distinguished honorees.

Michael Wu was also interviewed in World Biz Magazine where he shared insights into Amber Group’s mission and factors driving the company’s phenomenal growth. Read the interview.

“At Amber Group, we want to help create a future where digital assets empower people with opportunity and agency. This is at the heart of our mission. The road ahead is still long but we are honoured to be selected as a winner of this award,” said Michael Wu, co-founder and CEO of Amber Group.

World Biz Magazine’s Top 100 Innovation CEO Awards celebrates business leaders across the globe that are making major strides in their industries. It recognizes product, service, functional, strategic, and managerial innovation. It also recognizes individuals showing exceptional commercial insight and market integrity. Sustainability forms a key cornerstone of the awards and is an integral part of the selection criteria. Every year over 40,000 leaders are shortlisted and following a stringent evaluation process, only 100 winners are selected.

Mike Walters, Editor in Chief of World Biz Magazine: “We are pleased to announce Michael Wu as a recipient of the Award. To be highlighted within the Top 15 of the 100 winners is a testament to the pivotal role of Amber Group under Michael’s leadership in shaping the future of the crypto industry. Aside from its innovative technologies and exciting growth, the company is uniquely focused on transforming the financial ecosystem to be one that is more progressive, inclusive, transparent and sustainable.”

—————————–

About World Biz Magazine

World Biz Magazine is the leading global C-Suite business journal with a readership spanning 32 countries, WBM focuses on leadership, innovation, investment and social responsibility. www.worldbizmagazine.com

Contact WBM at: awards@worldbizmagazine.com

——————————–

About Amber Group

Amber Group is a leading digital asset company operating globally with offices in Asia, Europe, and the Americas. The firm provides a full range of digital asset services spanning investing, financing, and trading, servicing over 1,000 institutional clients and a growing number of individual investors worldwide. For more information about Amber Group, please visit www.ambergroup.io

Related Images

Image 1: Michael Wu, co-founder and CEO of Amber Group

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Michael Wu, co-founder and CEO of Amber Group

• Amlan International will exhibit and host multiple presentations at the XLVI ANECA 2022 Annual Congress and sponsor a half-day program on animal welfare topics
• Phylox^® Feed, Amlan’s new natural non-pharmaceutical solution to support optimum performance economics as antibiotics and anticoccidial drugs are removed from poultry rations, will be highlighted for Mexican poultry producers at the event
• Results from a recent commercial trial on patented mineral-based product Varium^® will also be presented at the ANECA congress

CHICAGO, March 15, 2022 (GLOBE NEWSWIRE) — Poultry specialists in Mexico will have the opportunity to learn about new research and solutions to industry challenges, including the launch of a new solution, Phylox Feed, from Amlan International, at the upcoming XLVI ANECA 2022 Annual Congress. The event is presented by the National Association of Specialists in Poultry Sciences (ANECA) and will be held from Tuesday, March 29, to Friday, April 1, 2022, at Hotel Azul Ixtapa in Ixtapa Zihuatanejo, Mexico.

Phylox is a natural non-pharmaceutical solution for poultry that supports optimum bird performance and the economics of poultry production. The active ingredients in Phylox have been demonstrated through independent research to interrupt the life cycle of various Eimeria species, the causative agents in coccidiosis. The synergistic blend of bioactive phytochemicals in Phylox also helps strengthen bird intestinal integrity and supports strong, natural immune function.

“Coccidiosis can cause significant health and performance issues for birds and has traditionally required pharmaceutical solutions, ionophores, or other antibiotic products to control field outbreaks,” said Dr. Wade Robey, VP of Marketing and Product Development. “With the launch of Phylox, producers in Mexico now have the opportunity to use a natural solution to help support bird health as drugs and other harsh chemical solutions continue to become more and more unacceptable to consumers.”

Amlan is taking part in multiple events throughout the ANECA congress including hosting a presentation at 9 a.m. on Thursday, March 31, by Dr. Elein Hernández, FES Cuatitlan, Universidad Nacional Autónoma de México (UNAM), on “Animal Welfare from the Perspective of Poultry Production.” Additionally, Amlan Sales Key Account Manager Andres Soto will present “Use of a Non-Antibiotic Growth Promoter in Chickens” at 9:45 a.m. on Thursday, March 31. Andres will discuss the use of the patented mineral-based Amlan feed additive Varium^® and the results seen during a trial on a commercial farm in Mexico.

“Pathogens like Salmonella and Clostridium perfringens, the causative agent of necrotic enteritis, are common challenges right now for poultry producers in Mexico, particularly if poultry are raised antibiotic-free,” said Margarita Santa, Director of Sales for Latin America. “Our mineral-based feed additives like Varium can help protect the intestinal environment from enteric pathogens and the negative health, welfare and economic effects they cause.”

During the congress Amlan will be hosting a half-day program starting at 9 a.m. on Thursday, March 31, 2022, that will focus on animal welfare issues. Discussion topics include the management and transportation of birds, broiler breeder feed and welfare, and the importance of animal welfare culture in companies.

Further details about the XLVI ANECA 2022 Annual Congress can be found here. For more information about Phylox, Varium or other Amlan products, contact info@amlan.com.

Company Information

Amlan is the animal health business of Oil-Dri Corporation of America, leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process their unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country; associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact
press@amlan.com

DUBAI, Arab Emirates, March 15, 2022 (GLOBE NEWSWIRE) — Carl Runefelt, crypto investor & entrepreneur and founder of TheMoon Group, has announced his official partnership with Formula 2 & driver Ralph Boschung. An avid fan of racing, Runefelt’s multi-million-dollar sponsorship puts his name “The Moon” at the forefront of Formula 2.

When asked about the sponsorship opportunity, Runefelt responded: “Bringing mass crypto adoption is my goal for 2022. Not only do I wish to bring more awareness to crypto but also child disabilities. Formula 2 gives me a platform for both subjects that are near and dear to my heart. Crypto has built my wealth over the years, which has allowed me to make major donations to foundations that help children with major disabilities such as Down Syndrome, which my little brother has.”

Runefelt and Boschung will collect crypto donations for disabled children at every of the 14 upcoming F2 races in the season 2022 through a QR code, which is printed unmissable at the nose of the car, or the website carlrunefelt.com/racing4charity. 100% of the donations will go directly to a selected charity project.”

“Bringing these two worlds together, I know I can help the world a little bit. I 100% believe in Ralph, as we are very good friends with similar mindset.” – Runefelt

The unveiling of the crypto racing car occurred in Valencia, Spain, and plans to hit the racetrack at the upcoming race in Bahrain (18.03.2022 – 20.03.2022).

Boschung is entering his fifth season in F2 this year, which will also be his third with Campos.

CONTACT INFORMATION:

TheMoon Group
Benjamin Drews
b.drews@moongroup.com

Related Images

Image 1: Carl “The Moon” Runefelt sponsorship deal with Formula 2 & driver, Ralph Boschung

Carl Runefelt sitting together with Formula 2 driver Ralph Boschung in front of the Campos Racing car.

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Carl “The Moon” Runefelt sponsorship deal with Formula 2 & driver, Ralph Boschung